Biotechnology
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED
* Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor * Inmagene retains rights to develop and commerciali...
2024-02-02 22:00
1521
Promising Clinical Results on the World's First Use of BCMA CAR-T to Treat Immune Mediated Necrotizing Myopathy (IMNM) Published on the Proceedings of the National Academy of Sciences (PNAS)
SHANGHAI, NANJING, China and SAN JOSE, Calif., Jan. 31, 2024 /PRNewswire/ -- On Jan. 30, 2024, PNAS published the research paper titled "Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR T-cell therapy." The paper analyzed results using the fully human B ...
2024-02-01 11:07
1607
Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development
TAIPEI, Jan. 31, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead investor is China Development Industrial Bank (CDIB), with s...
2024-02-01 00:00
1356
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland
- First manufacturing run successful for MFG7 facility at the Ireland site - Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland, Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Researc...
2024-01-31 17:31
2182
WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development
SHANGHAI, Jan. 30, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platfor...
2024-01-31 10:43
2562
XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics Discovery
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation to advance the discovery and evolution of groundbreaking th...
2024-01-30 21:00
1267
Singleron launches the AccuraSCOPE® Single Cell Transcriptome
COLOGNE, Germany, Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine,announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length...
2024-01-30 18:05
1173
DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD
* The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD. • DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor with excellent in vivo efficacy and safety profile in preclinical studies. * This project fur...
2024-01-30 16:32
1506
Vesicure Therapeutics made notable advancements using exosomes to target KRAS mutation
SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene. This technology has emerged as a great strategy for treating a range of diseases, including cancer, viral infections, and genetic...
2024-01-29 21:30
1314
Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.
SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for patients with...
2024-01-29 21:08
1453
Crystal Bio Welcomes Dr. Shiaw-Lin (Billy) Wu as Co-Founder and Chief Scientific Officer
CRANBURY, N.J., Jan. 29, 2024 /PRNewswire/ -- Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr.Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO). Dr. Wu brings with him more than three decades of experience in the field of...
2024-01-29 21:00
971
Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders
SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the charge in small activating RNA (saRNA) therapeutics, announces a formal collaboration with University Medical Center Utrecht, affiliated withUtrecht University. This strategic ...
2024-01-29 21:00
1068
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU
SHANGHAI, Jan. 29, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the release of ...
2024-01-29 16:17
1327
Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
* Glenmark will be responsible for further developing, registering, and commercializing Envafolimab inIndia, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. * Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additio...
2024-01-25 18:00
1599
Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 25, 2024 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the interi...
2024-01-25 16:56
1386
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse bioprocessing solutions for global clients - WuXiaADCC PLU...
2024-01-25 08:30
1351
WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit
CHENGDU, China, Jan. 24, 2024 /PRNewswire/ -- Kicking off the New Year with remarkable achievements,Chengdu-based WestGene made a significant impact at the 3rd mRNA-Based Therapeutics Summit inBerlin, Germany. Renowned for her pivotal role in mRNA research, Dr.Xiangrong Song, co-founder and CEO o...
2024-01-24 21:32
1309
Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI
* Results showed partial response being confirmed in 7 out of 42 patients * Partial response was observed in 3 out of 8 patients who were previously treated by immunotherapy SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in...
2024-01-24 21:00
1329
PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions
Eli Lilly and Company, Santec Holdings Corporation participated in the round TOKYO, Jan. 24, 2024 /PRNewswire/ -- TOKYO, Jan. 24, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protei...
2024-01-24 16:00
1183
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 23, 2024 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration (FDA) ofthe United States to init...
2024-01-24 12:40
1255
Week's Top Stories
Most Reposted
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 318 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 302 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
[Picked up by 272 media titles]
2024-05-10 15:20
Where does China's production capacity come from?
[Picked up by 258 media titles]
2024-05-10 12:01Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
8752
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
2024-05-10 15:20
8117
Where does China's production capacity come from?
2024-05-10 12:01
7954
China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering
2024-05-10 21:20
4980